These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 25943068)

  • 1. Programmed cell death-1 inhibition in lymphoma.
    Hawkes EA; Grigg A; Chong G
    Lancet Oncol; 2015 May; 16(5):e234-45. PubMed ID: 25943068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
    Cheah CY; Fowler NH; Neelapu SS
    Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
    Ansell SM
    J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting immune checkpoints in lymphoma.
    Ansell SM
    Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
    Tsirigotis P; Savani BN; Nagler A
    Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
    Hamid O; Carvajal RD
    Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
    Bryan LJ; Gordon LI
    Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
    Swaika A; Hammond WA; Joseph RW
    Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies.
    Bryan LJ; Gordon LI
    Oncology (Williston Park); 2015 Jun; 29(6):431-9. PubMed ID: 26091677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
    Xia Y; Jeffrey Medeiros L; Young KH
    Biochim Biophys Acta; 2016 Jan; 1865(1):58-71. PubMed ID: 26432723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.
    Nastoupil LJ; Neelapu SS
    Curr Oncol Rep; 2015 Jul; 17(7):30. PubMed ID: 25986722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PD-1 blockade therapy in lymphoid malignancies].
    Nishikori M; Takaori-Kondo A
    Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1-targeted immunotherapy: recent clinical findings.
    Brahmer JR
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-PD-1 therapy in melanoma.
    Homet Moreno B; Parisi G; Robert L; Ribas A
    Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
    Allen PB; Gordon LI
    Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.
    Henick BS; Herbst RS; Goldberg SB
    Expert Opin Ther Targets; 2014 Dec; 18(12):1407-20. PubMed ID: 25331677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-PD-1 antibody: basics and clinical application].
    Tanaka Y; Okamura H
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
    Robert C; Soria JC; Eggermont AM
    Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.